Abstract:BACKGROUND:Antiviral therapy cannot completely block the progression of hepatitis B to hepatocellular carcinoma (HCC). Furthermore, there are few predictors of early HCC progression and limited strategies to prevent progression in patients with HBV-related cirrhosis who receive nucleos(t)ide analog (NA) therapy. AIM:The study aim was to clarify risk factors and the diagnostic value of alpha-fetoprotein (AFP) for HCC progression in NA-treated hepatitis B virus (HBV)-related cirrhosis patients. METHODS:In this retrospective cross-sectional study, we analyzed the clinical data of 266 patients with HBV-related cirrhosis who received NA treatment between February 2014 and April 2020 at Zhejiang Provincial People's Hospital. The patients were divided into two groups, 145 who did not progress to HCC (No-HCC group), and 121 who progressed to HCC during NA treatment (HCC group). The logistic regression analysis was used to analyze the risk factors of HCC progression. The diagnostic value of AFP for HCC was evaluated by receiver operating characteristic (ROC) curve analysis. RESULTS:Univariate analysis showed that age ≥ 60 years (P = 0.001), hepatitis B and alcoholic etiology (P = 0.007), smoking history (P < 0.001), family history of HBV-related HCC (P = 0.002), lamivudine resistance (P = 0.011), HBV DNA negative (P = 0.023), aspartate aminotransferase > 80 U/L (P = 0.002), gamma-glutamyl transpeptidase > 120 U/L (P = 0.001), alkaline phosphatase > 250 U/L (P = 0.001), fasting blood glucose (FBG) ≥ 6.16 (mmol/L) (P = 0.001) and Child-Pugh class C (P = 0.005) were correlated with HCC progression. In multivariate analysis, age ≥ 60 years [hazard ratio (HR) = 3.089, 95% confidence interval (CI): 1.437-6.631, P = 0.004], smoking history (HR = 4.001, 95%CI: 1.836-8.716, P < 0.01), family history of HBV-related HCC (HR = 6.763, 95%CI: 1.253-36.499, P < 0.05), lamivudine resistance (HR = 2.949, 95%CI: 1.207-7.208, P = 0.018), HBV DNA negative (HR = 0.026, 95%CI: 0.007-0.139, P < 0.01), FBG ≥ 6.16 mmol/L (HR = 7.219, 95%CI: 3.716-14.024, P < 0.01) were independent risk factors of HCC progression. ROC of AFP for diagnosis of HCC was 0.746 (95%CI: 0.674-0.818). A cutoff value of AFP of 9.00 ug/L had a sensitivity of 0.609, and specificity of 0.818 for diagnosing HCC. CONCLUSION:Age ≥ 60 years, smoking history, family history of HCC, lamivudine resistance, HBV DNA negative, FBG ≥ 6.16 mmol/L were risk factors of HCC progression. Serum AFP had limited diagnostic value for HCC.

Risk factors of hepatocellular carcinoma in patients with HBV-related liver cirrhosis receiving nucleos (t) ide analogues treatment

Analysis of risk factors associated with the development of hepatocellular carcinoma in hepatitis B cirrhosis patients under nucleos(t)ide analog therapy

Clinical features of patients developing primary hepatocellular carcinoma during anti-HBV therapy with nucleos(t) ide analogues

Incidence And Predictors Of Hepatocellular Carcinoma In Chinese Hepatitis B Virus-Related Cirrhotic Patients Receiving Antiviral Therapy: A Retrospective Cohort Study

Long-term prognosis of patients with HBV-related decompensated cirrhosis treated by nucleos( t)ide analogues

Role of early on-treatment serum HBV RNA declines in predicting hepatocellular carcinoma risk in patients with chronic hepatitis B

Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues

Risk Factors for Hepatocellular Carcinoma in Cirrhotic Patients with Chronic Hepatitis B

Non-Achievement of Alanine Aminotransferase Normalization Associated with the Risk of Hepatocellular Carcinoma during Nucleos(t)ide Analogue Therapies: A Multicenter Retrospective Study

Hepatocellular Carcinoma Progression in Hepatitis B Virus-Related Cirrhosis Patients Receiving Nucleoside (acid) Analogs Therapy: A Retrospective Cross-Sectional Study.

Real-world Study on Clinical Outcomes of Nucleos(t)ide Analogues Antiviral Therapy in Patients with Chronic Hepatitis B.

Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model

Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment

Interferon-based Treatment is Superior to Nucleos(t)ide Analog in Reducing HBV-related Hepatocellular Carcinoma for Chronic Hepatitis B Patients at High Risk

Usefulness of the Fibrosis-4 Index and Alanine Aminotransferase at 1 Year of Nucleos(t)ide Analog Treatment for Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients

The effects of nucleos(t)ide analogues treatment on prognosis of patients with chronic hepatitis B - related hepatocellular carcinoma

[Timing and Selection of Antiviral Therapy with Nucleos(t)ide Analogues for Prevention of Hepatitis B Virus-Related HCC].

Randomized Clinical Trial: Nucleos(t)ide Analogues Improved Survival of CHB-related HCC Patients Via Reducing Severity and Progression of Malignancy

Risk factors for hepatocellular carcinoma in cirrhosis: A comprehensive analysis from a decade-long study

Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis

Long-term effect of nucleoside(tide) analogues and interferon treatment on hepatocellular carcinoma occurrence and death in chronic HBV-infected patients